Somerset Drug Patent Portfolio
Somerset owns 1 orange book drug protected by 3 US patents Given below is the list of Somerset's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7150881 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | 12 Jun, 2018 | Expired |
| US7070808 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | 10 May, 2018 | Expired |
| US7638140 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | 10 May, 2018 | Expired |
Latest Legal Activities on Somerset's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Somerset.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 31 Jan, 2022 | US7638140 |
|
Maintenance Fee Reminder Mailed
Critical
| 16 Aug, 2021 | US7638140 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Dec, 2017 | US7070808 |
|
Correspondence Address Change
Critical
| 25 Apr, 2014 | US7070808 |
|
Correspondence Address Change
Critical
| 25 Apr, 2014 | US7638140 |
| Post Issue Communication - Certificate of Correction | 01 Feb, 2011 | US7638140 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Dec, 2009 | US7638140 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Dec, 2009 | US7638140 |
|
Issue Notification Mailed
Critical
| 09 Dec, 2009 | US7638140 |
|
Application Is Considered Ready for Issue
Critical
| 16 Nov, 2009 | US7638140 |
| Dispatch to FDC | 16 Nov, 2009 | US7638140 |
|
Issue Fee Payment Verified
Critical
| 11 Nov, 2009 | US7638140 |
|
Issue Fee Payment Received
Critical
| 11 Nov, 2009 | US7638140 |
| Mail Examiner's Amendment | 22 Oct, 2009 | US7638140 |
|
Pubs Case Remand to TC
Critical
| 02 Sep, 2009 | US7638140 |
Somerset's Family Patents
Recent FDA approvals and tentative approvals for Somerset
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Rilpivirine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 20 Aug, 2025 |
| Eltrombopag Olamine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 05 Aug, 2025 |
Somerset Drug List
Given below is the complete list of Somerset's drugs and the patents protecting them.
1. Emsam
Emsam is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7150881 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
12 Jun, 2018
(7 years ago)
| Expired |
| US7070808 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
10 May, 2018
(7 years ago)
| Expired |
| US7638140 | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
10 May, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emsam's drug page